Halozyme Therapeutics Operating Expenses 2010-2024 | HALO

Halozyme Therapeutics operating expenses for the twelve months ending September 30, 2024 were $0.470B, a 0.15% increase year-over-year.

  • Halozyme Therapeutics annual operating expenses for 2023 were $0.492B, a 25.24% increase from 2022.
  • Halozyme Therapeutics annual operating expenses for 2022 were $0.393B, a 134.51% increase from 2021.
  • Halozyme Therapeutics annual operating expenses for 2021 were $0.167B, a 35.73% increase from 2020.

Halozyme Therapeutics Operating Expenses 2010-2024 | HALO

  • Halozyme Therapeutics annual operating expenses for 2023 were $0.492B, a 25.24% increase from 2022.
  • Halozyme Therapeutics annual operating expenses for 2022 were $0.393B, a 134.51% increase from 2021.
  • Halozyme Therapeutics annual operating expenses for 2021 were $0.167B, a 35.73% increase from 2020.